In this article, Dr. Asma Patel, VP of Global Commercial and Scientific Consulting-Drug Product at Quotient Sciences discusses the Impact of Patient-Centric Formulations on CDMO market.
2025 formulation outsourcing is being reshaped by advanced modalities and patient-centric design. Peptides and RNA therapies are driving sponsors to partner with specialized CDMOs that offer integrated science, adaptive GMP manufacturing, and robust regulatory support.
Quotient Sciences’ Translational Pharmaceutics® enables rapid make–test cycles and data-driven optimization, accelerating development by 12+ months while reducing cost and risk.
Continue reading the full article on PharmaTech